Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:PRX
CUSIPN/A
Phone+1-845-5735500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Par Pharmaceutical Companies (NYSE:PRX) Frequently Asked Questions
What is Par Pharmaceutical Companies' stock symbol?
Par Pharmaceutical Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRX."
Who are Par Pharmaceutical Companies' key executives?
Par Pharmaceutical Companies' management team includes the folowing people:
- Paul V. Campanelli, Chief Executive Officer (Age 54)
- Michael A. Tropiano, Chief Financial Officer, Executive Vice President (Age 57)
- Terrance John Coughlin, Chief Operating Officer (Age 52)
- Thomas J. Haughey, Chief Administrative Officer, General Counsel (Age 51)
Has Par Pharmaceutical Companies been receiving favorable news coverage?
Headlines about PRX stock have trended positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Par Pharmaceutical Companies earned a news and rumor sentiment score of 0.28 on Accern's scale. They also gave news stories about the healthcare company an impact score of 48.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Par Pharmaceutical Companies.
How do I buy shares of Par Pharmaceutical Companies?
Shares of PRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Par Pharmaceutical Companies?
Par Pharmaceutical Companies' mailing address is 1 Ram Ridge Rd, CHESTNUT RIDGE, NY 10977-6714, United States. The healthcare company can be reached via phone at +1-845-5735500.
MarketBeat Community Rating for Par Pharmaceutical Companies (NYSE PRX)
MarketBeat's community ratings are surveys of what our community members think about Par Pharmaceutical Companies and other stocks. Vote "Outperform" if you believe PRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
